Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...

Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q2 2025 earnings at $3.22 EPS, Q3 2025 earnings at $3.04 EPS, Q4 2025 earnings at $2.84 EPS, FY2025 earnings at $11.86 EPS, FY2026 ...

Leerink Partnrs analyst T. Smith now expects that the company will earn $0.60 per share for the year, down from their previous estimate of $0.61. The consensus estimate for Genfit’s current full ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...

Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF following the termination of Eli Lilly (NYSE:LLY)'s study. However, the ...

In a report released on January 9, Thomas Smith from Leerink Partners reiterated a Buy rating on Climb Bio (CLYM – Research Report). The company’s shares closed last Friday at $2.00.

On Friday, Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over the past six months, creating an opportunity to ...

MONTREAL, Feb. 3, 2025 /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in ...